Benefit-risk assessment in Pharmacovigilance and in PBRERs MasterClass with a special focus on PSURs - US edition

Dimitris has got 12 years of experience in providing strategic input into safety aspects of assigned product(s), lead the pharmacovigilance processes and product safety reviews, review SOPs and guidelines, provide scientific input in signal, risk management and benefit risk assessment outputs and reviews and act as key person for regulatory or internal audits and inspections.

In his previous roles as safety expert, he was responsible for the development of the company’s benefit-risk assessment framework, the signal detection strategy e.g., quantitative, and qualitative signal detection methods using internal and external databases (EVDAS, VigiBase, FAERS, VAERS, JADER) as also the Risk Management and risk minimization measures processes and implementation. Through his career Dimitris gained substantial and solid knowledge and experience in different aspects of Drug Safety and Pharmacovigilance such as Signal Detection, RMPs, PBRERs/ PSURs, DSURs, safety communications (e.g., Direct Healthcare Professional Communication/ Dear Investigator Letter). He participated in various successful FDA and EMA submission applications either as a team member or as team leader.

Dimitris is a Pharmacovigilance tutor and trainer and participates in various conferences as a speaker. Also, Dimitris is a guest lecturer at the Master of Science (MSc) program Drug and Regulatory Affairs of the Pharmaceutical Department of the University of Nicosia (Cyprus).

Dimitris is biologist by training, acquired a MSc in Medicinal Chemistry from University of Patras in Greece, a MSc in Health Policy and Planning from the Open University of Cyprus and he holds a PhD in Cell and Molecular Biology from Free University of Berlin.